Phase Ib/II Clinical Study of IAH0968 in Combination With Gemcitabine and Cisplatin for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors and Cholangiocarcinoma

This study is testing a new experimental drug, IAH0968, combined with standard chemotherapy to see if it works better at fighting advanced, HER2-positive cancers. HER2-positive means your cancer cells have a specific protein that helps them grow, and this trial aims to see if adding the new drug can help stop that growth more effectively.

This study is for adults 18 and older with advanced, HER2-positive tumors that haven't responded to previous treatments. You must be active enough to handle daily tasks and have a measurable tumor that hasn't been treated with radiation or surgery.

Participants will receive a combination of chemotherapy drugs and potentially the new study drug, IAH0968. Doctors will carefully monitor your health throughout the study to check how well the treatment is working and watch for any side effects.

The study is currently taking place in Shanghai, China. The exact status of the trial is currently unknown, so it is best to speak with a doctor to see if they are still enrolling participants.